Angina Treatment with EECP Therapy in India

Living With Chest Pain Is Not the Only Option

Most angina patients who come to FHCC have been managing their condition for months or years. They’ve been on nitrates, beta-blockers, calcium channel blockers — sometimes all three. The medication helps, but it doesn’t fix the problem. The chest pain returns. The breathlessness comes back on the next walk, the next flight of stairs, the next moment of stress.

Many have been told the next step is bypass surgery or angioplasty. Some have already had those procedures — and still have angina. They’ve been told “nothing more can be done” or “this is just how it is now.”

What most of these patients haven’t been told is that a third option exists. One that is non-surgical, non-invasive, clinically proven, and FDA-cleared specifically for the treatment of angina. One that doesn’t just suppress symptoms but actually improves blood supply to the heart muscle.

That treatment is EECP therapy. It is not new. It is not experimental. It has been used for decades in cardiac care globally, endorsed by the American College of Cardiology and the American Heart Association, and supported by over 100 peer-reviewed clinical studies. And it is the core specialty at FHCC.

If you have angina — newly diagnosed, long-standing, post-bypass, or refractory — this page will explain clearly whether EECP therapy is right for you, what to expect, and why FHCC is the right place to receive it.

What Type of Angina Do You Have?

Angina is chest pain or discomfort that occurs when the heart muscle is not receiving enough oxygen-rich blood. It is most commonly caused by narrowing of the coronary arteries due to plaque buildup — a condition called coronary artery disease (CAD). But not all angina is the same, and the type you have matters when determining whether EECP therapy is the right treatment.

Stable Angina (H3) The most common form. Chest pain or tightness triggered predictably by physical exertion, stress, or cold — and usually relieved by rest or nitroglycerin within a few minutes. Stable angina means your coronary arteries are significantly narrowed, and your heart is not getting enough blood when demand increases. This is the primary and most well-studied indication for EECP therapy. Most patients at FHCC presenting with stable angina see significant improvement — fewer episodes, reduced severity, better exercise tolerance — after completing their EECP course.

Refractory Angina (H3) Refractory angina is defined as persistent chest pain that continues despite maximum medical therapy — meaning you are already on the full range of anti-anginal medications at optimal doses — and where bypass surgery or angioplasty is either not technically feasible, has already been performed, or carries risks that outweigh the benefits. This is the patient group for whom EECP was originally developed and received its FDA clearance. If you have been told “there’s nothing more we can do,” FHCC specifically wants to hear from you. Refractory angina is one of our most common — and most successfully treated — presentations.

Post-Revascularization Angina (H3) A significant number of patients who undergo bypass surgery (CABG) or angioplasty and stenting continue to experience angina afterward. This can occur because not all arteries were suitable for bypassing, because grafts or stents narrow over time (restenosis), or because the disease has progressed in other vessels. For these patients, repeat surgery carries substantially higher risk and may not be technically possible. EECP therapy is an evidence-based, non-invasive option for this group — and one that many post-bypass patients at FHCC have used to achieve the relief their surgery did not deliver.

Microvascular Angina / Cardiac Syndrome X (H3) Some patients experience typical angina chest pain despite having normal or near-normal coronary arteries on angiography. This is microvascular angina — caused by dysfunction in the tiny blood vessels (microvasculature) within the heart muscle itself. It is more common in women and in patients with diabetes. Standard interventional treatments are not applicable because there are no large blockages to bypass or stent. EECP therapy has shown specific benefit in improving microvascular function, making it one of the few effective treatments for this underdiagnosed and often frustrating condition.

Variant (Prinzmetal) Angina (H3) Caused by temporary coronary artery spasm — sometimes in arteries that are otherwise relatively healthy — variant angina typically occurs at rest and can be severe. While medication remains the primary treatment, EECP therapy’s ability to reduce vascular inflammation and improve endothelial function makes it a valuable adjunct, particularly in patients with recurrent episodes despite medication.

How EECP Therapy Treats Angina — The Science, Simply Explained

EECP stands for Enhanced External Counterpulsation. It is a non-invasive cardiac treatment in which pneumatic cuffs are wrapped around the calves, thighs, and buttocks. These cuffs are connected to a computer system that reads your ECG in real time and inflates the cuffs at a precise moment — during diastole, the rest phase between heartbeats — and deflates them just before the next heartbeat begins.

This timed inflation-deflation cycle creates two simultaneous effects: it pushes a wave of oxygen-rich blood up toward the heart during diastole, increasing the coronary perfusion pressure exactly when the coronary arteries are most receptive to receiving blood; and it reduces the resistance the heart pumps against during systole, reducing cardiac workload.

Done once, this is a mechanical benefit. Done consistently over 35 sessions, the body responds biologically — and this is where the lasting benefit comes from.

The Biology: Why EECP Creates Lasting Relief

The repeated high-pressure blood flow waves generated by EECP create a phenomenon called fluid shear stress on the inner lining of blood vessels — the endothelium. This is the same biological stimulus that vigorous aerobic exercise generates. The endothelium responds by upregulating the production of nitric oxide (NO) — the molecule responsible for blood vessel relaxation and dilation — and by releasing growth factors, including vascular endothelial growth factor (VEGF), that stimulate the formation of new blood vessels.

This process — called angiogenesis — is the cornerstone of EECP’s lasting benefit in angina. New collateral blood vessels grow around the narrowed or blocked coronary arteries, providing the heart muscle with alternative supply routes. These are, in the most literal biological sense, natural bypass channels — built by your own body, around the blockages that are causing your angina.

Unlike a surgical bypass, which creates one or a few large conduits, collateral angiogenesis creates a network of smaller vessels distributed across the area of ischemic heart muscle. The result is broader, more diffuse improvement in myocardial blood supply.

Additionally, EECP reduces inflammatory cytokines associated with endothelial dysfunction, improves the function of the left ventricle, reduces sympathetic nervous system activation (which contributes to coronary artery spasm and angina triggers), and decreases the neurohormonal stress response that worsens cardiac ischemia.

The cumulative result: fewer angina episodes, reduced severity, improved exercise tolerance, reduced need for fast-acting nitrates, and better quality of life — effects that are documented to persist for 3 to 5 years or more after a single treatment course.

What a Session Feels Like

You arrive at FHCC’s EECP therapy suite in comfortable clothing. Our trained therapist attaches ECG leads to monitor your heart rate in real time and wraps the pneumatic cuffs around your calves, thighs, and buttocks. The session begins.

The cuffs inflate and deflate in rhythm with your heartbeat. The sensation is similar to a firm, rhythmic leg massage — pressure that builds and releases with each beat of your heart. It is not painful. Most patients read, listen to music, or simply rest during sessions.

Each session is one hour. When it ends, you remove the cuffs, get dressed, and leave. There is no recovery period. No grogginess. No restrictions on eating or driving. You can return to your normal daily activities immediately.

The Treatment Course

A standard EECP course consists of 35 sessions, conducted five days per week over seven weeks. This is the protocol established through decades of clinical research and the basis of FDA clearance. It is not arbitrary — studies show that the full 35-session course produces significantly better and more durable outcomes than partial courses.

Many patients begin noticing improvement in angina frequency and walking capacity within the first 10–15 sessions. The full benefit — maximum collateral vessel formation and endothelial improvement — is achieved by the end of the complete course, with continued improvement in the weeks following as the body continues to consolidate the vascular changes.

Is EECP Therapy the Right Treatment for You?

EECP therapy at FHCC is appropriate for a broad range of angina patients. You are likely a good candidate if one or more of the following applies:

You have stable or chronic angina that is not fully controlled by your current medications, and chest pain is still limiting your daily activities, exercise capacity, or quality of life.

You have been advised to have bypass surgery or angioplasty but want to explore a non-surgical option first, or want a second opinion before committing to an invasive procedure.

You have already had bypass surgery or coronary stenting and still experience angina — meaning the revascularization did not fully resolve your symptoms, or the disease has progressed in other vessels.

You have been diagnosed with refractory angina — defined as persistent chest pain despite maximum medical therapy, where further revascularization is not technically feasible or is too high risk.

You have diffuse coronary artery disease — multiple vessels affected over long segments — that is not suitable for bypass or stenting because the anatomy does not allow for targeted intervention.

You have microvascular angina or Cardiac Syndrome X — chest pain with normal or near-normal coronary arteries — for which invasive treatment is not applicable.

You are an older patient or have significant comorbidities (diabetes, kidney disease, lung disease, prior stroke) that make surgery a high-risk option.

You want to reduce your dependence on fast-acting nitrates and other anti-anginal medications, and are looking for a treatment that addresses the underlying cause rather than just suppressing episodes.

You are in cardiac rehabilitation following a heart attack and want to accelerate vascular recovery and improve exercise tolerance as part of your rehabilitation program.

Who May Not Be Suitable

EECP therapy is not appropriate for all patients, and our cardiologists screen every patient carefully before beginning treatment. General contraindications include decompensated heart failure requiring urgent intervention, significant aortic valve regurgitation, active deep vein thrombosis or recent pulmonary embolism, active bleeding or coagulation disorders, uncontrolled severe hypertension (above 180/110 mmHg at baseline), certain cardiac arrhythmias that would interfere with ECG synchronization, and pregnancy. Our pre-treatment consultation and investigation protocol is designed to identify any of these factors before therapy begins. If a contraindication exists, we will tell you clearly and advise on the most appropriate alternative.

EECP Therapy, Bypass Surgery, and Angioplasty — An Honest Comparison

Bypass surgery (CABG) and angioplasty with stenting (PCI) are valuable, life-saving procedures for the right patients. FHCC does not dismiss them. If one of those procedures is genuinely the best option for you, our cardiologists will say so clearly.

But they are not the right option for every angina patient. And for many patients — particularly those with diffuse disease, prior revascularization, high surgical risk, or refractory angina — EECP therapy delivers comparable symptomatic relief more safely, more affordably, and without the risks and recovery burden of surgery.

Here is an honest side-by-side comparison:

EECP Therapy at FHCC Completely non-invasive — no surgery, no incisions, no anesthesia, no catheter. No hospital admission required. No recovery period — normal activities resume the same day after each session. No risk of procedural complications such as infection, bleeding, stroke, or anaesthetic reaction. Suitable for patients who have already had bypass or stenting and still have symptoms. Suitable for patients with diffuse disease not amenable to targeted revascularization. Benefits typically last 3–5 years or longer. A fraction of the cost of surgical intervention. Can be repeated with a booster course if symptoms return years later.

Bypass Surgery (CABG) Major open-heart surgery under general anaesthesia. 5–7 days in hospital. 6–12 weeks recovery before return to normal activities. Risks include wound infection, sternal wound complications, stroke, cognitive decline (“pump head”), atrial fibrillation, and graft occlusion over time. Not suitable for all coronary anatomies. Re-operation for recurrent disease carries substantially higher risk than the initial procedure.

Angioplasty / Stenting (PCI) Catheter-based procedure — less invasive than surgery but still invasive. Shorter hospital stay and recovery than CABG. Risk of in-stent restenosis (re-narrowing within the stent) in 10–30% of cases depending on stent type and vessel characteristics. Requires prolonged dual antiplatelet therapy with bleeding risk implications. Not feasible for long, diffuse, or calcified lesions in multiple vessels.

The key point for patients with stable or refractory angina is this: EECP therapy does not create a mechanical conduit around a blockage the way surgery does. What it does is stimulate the body to grow its own collateral vessels — a more distributed, biologically integrated improvement in coronary blood supply that is not limited by anatomy, does not require a suitable bypass target, and does not carry any procedural risk.

For the right patient, this is not a compromise. It is a superior option.

The Clinical Evidence Behind EECP for Angina

EECP therapy is not an experimental or fringe treatment. It has been in clinical use for over three decades, is FDA-cleared specifically for the treatment of stable and refractory angina, and is supported by an extensive body of clinical research.

The International EECP Patient Registry (IEPR) — one of the largest real-world observational studies of EECP therapy — enrolled thousands of patients across multiple centres and consistently found that approximately 75–80% of angina patients completing EECP therapy reported clinically significant reductions in angina frequency and improved exercise tolerance. Patients typically moved down one or more CCS angina classes — for example, from Class III (angina limiting ordinary activity) to Class I (angina only with strenuous exertion) — and maintained those improvements at 6 and 12-month follow-up.

Multiple randomized controlled trials have confirmed EECP’s superiority over sham treatment in reducing angina frequency, decreasing nitroglycerin use, improving exercise duration on stress testing, and improving quality of life scores.

The American College of Cardiology (ACC) and American Heart Association (AHA) include EECP as a Class IIb recommendation in their stable ischemic heart disease guidelines for patients with refractory angina not suitable for revascularization. EECP also holds CE Mark approval in Europe and is endorsed by multiple international cardiac societies.

At FHCC, we use internationally certified EECP equipment and adhere to the treatment standards established by the International EECP Practitioners Association (IEECPA). Our protocols are not improvised — they follow the same parameters as those used in the clinical trials that established EECP’s evidence base.

How We Assess You Before Starting EECP Therapy

EECP therapy is not suitable for every patient with chest pain, and it is not started at FHCC without a proper cardiac evaluation. Before we recommend and begin therapy, our cardiologist conducts a thorough assessment that includes a detailed clinical history — including symptom pattern and duration, current medications, prior cardiac procedures, and cardiovascular risk factors. Resting ECG to assess baseline cardiac rhythm and rule out contraindications. Echocardiogram to evaluate left ventricular function, ejection fraction, wall motion abnormalities, and valve function. Stress test (treadmill/TMT or pharmacological stress echo) to document ischaemia and establish a baseline functional capacity against which to measure post-treatment improvement. Review of any prior coronary angiogram or CT coronary angiography reports. Blood tests including lipid profile, HbA1c, renal function, and cardiac biomarkers. A full review of your current cardiac medications and a discussion of appropriate optimization alongside EECP therapy.

This evaluation allows us to confirm that EECP therapy is appropriate for you, identify any contraindications, establish your angina severity and functional class, design the most effective treatment protocol, and set realistic, measurable outcome goals for your course.

If you bring your recent reports from another hospital or cardiologist, our team will review them at your first consultation and advise you whether additional investigations are needed before starting.

What Your EECP Treatment Journey Looks Like

Step 1 — Initial Consultation Your cardiologist at FHCC reviews your complete history, examines your investigations, and gives you an honest recommendation. If EECP therapy is appropriate, you receive a clear explanation of what the treatment involves, what results you can realistically expect, the full cost of the course, and your proposed schedule. There is no pressure and no upselling. If a different intervention is better suited to your situation, we will tell you that.

Step 2 — Baseline Assessment Before session one, we establish your baseline — angina frequency and severity scored on the CCS classification, exercise tolerance, current medication burden, and relevant cardiac function parameters. This gives us a clear before-and-after picture to track your progress objectively.

Step 3 — EECP Therapy — 35 Sessions Over 7 Weeks You attend five sessions per week, each lasting one hour. Morning, afternoon, or evening slots are available to fit your routine. Each session is conducted in FHCC’s dedicated EECP therapy suite and monitored by our trained EECP therapist. You arrive, the cuffs are applied, the session runs, you leave. Most patients integrate their sessions into their normal week without significant disruption.

Step 4 — Mid-Course Review (Around Session 17–18) Your cardiologist conducts a progress review approximately halfway through the course. We assess symptom changes, functional capacity, and any medication adjustments that may be appropriate. This mid-course check allows us to optimize the second half of your treatment based on your individual response.

Step 5 — Post-Course Assessment After session 35, we conduct a structured outcome assessment — repeat stress test, angina class scoring, quality-of-life evaluation, and relevant cardiac function review. Most patients complete the course at a significantly lower CCS class than when they started. You receive a detailed long-term cardiac management plan, including medication guidance and lifestyle recommendations.

Step 6 — Long-Term Follow-Up FHCC remains your cardiac care team after the course ends. We provide annual cardiovascular reviews and are available for consultation if symptoms change. If angina returns years down the line, a booster course of EECP therapy is available and has been shown to be safe and effective.

What EECP Therapy Typically Achieves for Angina Patients

Results vary by patient — depending on the severity and duration of disease, prior treatments, and individual cardiac anatomy — but the following outcomes are consistently documented in clinical literature and reflect what FHCC patients experience:

Significant reduction in angina frequency — many patients move from daily episodes to weekly or monthly. Reduced severity of each episode, with less need for fast-acting nitroglycerin. Improved exercise tolerance — patients who could not walk one block without chest pain can often walk 1–2 km or more after completing the course. Reduction in CCS angina class by one or more grades — for example, from Class III to Class I. Decreased anti-anginal medication burden — many patients are able to reduce nitrate use under their cardiologist’s supervision. Improved quality of life and ability to resume activities that angina had made impossible. Better sleep — including reduction or elimination of nocturnal angina episodes. Sustained benefits lasting 3–5 years or longer after a single course.

In patients with refractory angina specifically — the group most underserved by conventional treatment — EECP provides relief that nothing else has. The IEPR data shows that even patients who have had multiple prior revascularizations and are on maximal medical therapy achieve meaningful symptomatic improvement following EECP therapy.

Why Patients Choose FHCC for Angina Treatment with EECP

EECP Is Our Core Specialty — Not an Add-On Service Many centres in India now offer EECP. At FHCC, it is not a service added onto a general cardiology practice or a wellness clinic offering multiple therapies. It is what our centre is built around — our equipment, our team, our protocols, and our monitoring systems are all designed specifically for optimal EECP outcomes. This focused expertise translates into better results.

Cardiologist-Led Treatment, Not Technician-Administered Therapy At FHCC, your EECP course is designed, overseen, and reviewed by a qualified cardiologist. Your pre-treatment evaluation is a proper cardiac workup. Your mid-course review and post-course assessment are medical consultations. Many EECP providers delegate the clinical oversight to technicians and limit the doctor’s involvement to a brief initial screen. We do not.

Internationally Certified Equipment and Protocols We use EECP systems certified to international standards. Equipment calibration, session pressure settings, and ECG synchronization accuracy directly affect the quality of diastolic augmentation — which directly affects how well collateral vessel formation is stimulated. We do not compromise on equipment.

Honest, Evidence-Based Counselling If bypass surgery or stenting is genuinely the better option for your coronary anatomy, we will tell you. We do not oversell EECP to patients for whom a different intervention is more appropriate. This honesty is the foundation of our clinical reputation and our patient relationships.

Integrated Cardiac Care EECP therapy delivers its best results when combined with optimized medication, appropriate dietary modification, cardiovascular risk factor management, and structured follow-up. FHCC provides all of this as a cohesive program — not as a series of disconnected consultations. You leave with a complete cardiac management plan, not just a completed treatment course.